Abeona Therapeutics Inc (NASDAQ: ABEO) has seen a rise in its stock price by 5.84 in relation to its previous close of 7.36. However, the company has experienced a 1.17% gain in its stock price over the last five trading sessions. Proactive Investors reported 2023-11-27 that Abeona Therapeutics Inc shares jumped 15% to $4.96 in late-morning trading on Monday after the US Food and Drug Administration (FDA) said it would expedite a review of pz-cel (prademagene zamikeracel), the company’s proposed treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare, inherited connective-tissue disorder. The clinical-stage biopharmaceutical company had previously stated that it expected an FDA decision on priority-review status by late November.
Is It Worth Investing in Abeona Therapeutics Inc (NASDAQ: ABEO) Right Now?
Moreover, the 36-month beta value for ABEO is 1.47. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ABEO is 25.91M and currently, short sellers hold a 7.70% of that float. On April 12, 2024, ABEO’s average trading volume was 338.24K shares.
ABEO’s Market Performance
ABEO stock saw a decrease of 1.17% in the past week, with a monthly decline of -4.77% and a quarterly a decrease of 44.53%. The volatility ratio for the week is 6.31%, and the volatility levels for the last 30 days are 7.38% for Abeona Therapeutics Inc (ABEO). The simple moving average for the last 20 days is 2.30% for ABEO stock, with a simple moving average of 58.22% for the last 200 days.
Analysts’ Opinion of ABEO
Many brokerage firms have already submitted their reports for ABEO stocks, with Cantor Fitzgerald repeating the rating for ABEO by listing it as a “Overweight.” The predicted price for ABEO in the upcoming period, according to Cantor Fitzgerald is $4 based on the research report published on November 11, 2020 of the previous year 2020.
B. Riley FBR, on the other hand, stated in their research note that they expect to see ABEO reach a price target of $5. The rating they have provided for ABEO stocks is “Buy” according to the report published on September 18th, 2020.
SVB Leerink gave a rating of “Outperform” to ABEO, setting the target price at $6 in the report published on February 10th of the previous year.
ABEO Trading at 11.99% from the 50-Day Moving Average
After a stumble in the market that brought ABEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.54% of loss for the given period.
Volatility was left at 7.38%, however, over the last 30 days, the volatility rate increased by 6.31%, as shares sank -5.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +73.88% upper at present.
During the last 5 trading sessions, ABEO rose by +1.17%, which changed the moving average for the period of 200-days by +64.00% in comparison to the 20-day moving average, which settled at $7.59. In addition, Abeona Therapeutics Inc saw 55.49% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABEO starting from Seshadri Vishwas, who purchase 20,000 shares at the price of $4.39 back on Feb 06 ’24. After this action, Seshadri Vishwas now owns 528,260 shares of Abeona Therapeutics Inc, valued at $87,800 using the latest closing price.
Alvino Mark, the Director of Abeona Therapeutics Inc, sale 7,084 shares at $5.11 during a trade that took place back on Jan 17 ’24, which means that Alvino Mark is holding 62,816 shares at $36,199 based on the most recent closing price.
Stock Fundamentals for ABEO
Current profitability levels for the company are sitting at:
- -13.77 for the present operating margin
- 0.09 for the gross margin
The net margin for Abeona Therapeutics Inc stands at -15.48. The total capital return value is set at -0.95. Equity return is now at value -260.60, with -84.53 for asset returns.
Based on Abeona Therapeutics Inc (ABEO), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -6.85. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is -115.31.
Currently, EBITDA for the company is -45.0 million with net debt to EBITDA at 0.21. When we switch over and look at the enterprise to sales, we see a ratio of 58.2. The receivables turnover for the company is 1.43for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.15.
Conclusion
To wrap up, the performance of Abeona Therapeutics Inc (ABEO) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
